CN109464653A - A kind of novel prevention sucking pig diarrhea peptase and preparation method thereof - Google Patents
A kind of novel prevention sucking pig diarrhea peptase and preparation method thereof Download PDFInfo
- Publication number
- CN109464653A CN109464653A CN201811599053.4A CN201811599053A CN109464653A CN 109464653 A CN109464653 A CN 109464653A CN 201811599053 A CN201811599053 A CN 201811599053A CN 109464653 A CN109464653 A CN 109464653A
- Authority
- CN
- China
- Prior art keywords
- peptase
- sucking pig
- diarrhea
- novel prevention
- pig diarrhea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 36
- 230000002265 prevention Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims description 12
- 108090001060 Lipase Proteins 0.000 claims abstract description 17
- 239000004367 Lipase Substances 0.000 claims abstract description 17
- 102000004882 Lipase Human genes 0.000 claims abstract description 17
- 235000019421 lipase Nutrition 0.000 claims abstract description 17
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000005875 quercetin Nutrition 0.000 claims abstract description 16
- 102000030595 Glucokinase Human genes 0.000 claims abstract description 14
- 108010021582 Glucokinase Proteins 0.000 claims abstract description 14
- 108091005804 Peptidases Proteins 0.000 claims abstract description 14
- 108010021006 Tyrothricin Proteins 0.000 claims abstract description 14
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims abstract description 14
- 235000008206 alpha-amino acids Nutrition 0.000 claims abstract description 14
- GSXRBRIWJGAPDU-BBVRJQLQSA-N tyrocidine A Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 GSXRBRIWJGAPDU-BBVRJQLQSA-N 0.000 claims abstract description 14
- 229960003281 tyrothricin Drugs 0.000 claims abstract description 14
- RKLXDNHNLPUQRB-TVJUEJKUSA-N chembl564271 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]2C(C)SC[C@H](N[C@@H](CC(N)=O)C(=O)NC(=O)[C@@H](NC2=O)CSC1C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NC(=C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H]1NC(=O)C(=C\C)/NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)[C@H]3N[C@@H](CC(C)C)C(=O)NC(=O)C(=C)NC(=O)CC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C5=CC=CC=C5NC=4)CSC3)C(O)=O)C(C)SC2)C(C)C)C(C)SC1)C1=CC=CC=C1 RKLXDNHNLPUQRB-TVJUEJKUSA-N 0.000 claims abstract description 13
- 108010082567 subtilin Proteins 0.000 claims abstract description 13
- 239000004365 Protease Substances 0.000 claims abstract description 12
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims description 22
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 5
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical group O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 5
- 238000005286 illumination Methods 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 abstract description 19
- 230000001580 bacterial effect Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 5
- 231100000765 toxin Toxicity 0.000 abstract description 5
- 230000010224 hepatic metabolism Effects 0.000 abstract description 2
- 210000003494 hepatocyte Anatomy 0.000 abstract description 2
- 230000005727 virus proliferation Effects 0.000 abstract description 2
- 241000282898 Sus scrofa Species 0.000 description 40
- 230000006872 improvement Effects 0.000 description 10
- 241000700605 Viruses Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000001678 irradiating effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229930192956 Lavendustin Natural products 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical class [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- -1 streptomysin Chemical compound 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01002—Glucokinase (2.7.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a kind of novel prevention sucking pig diarrhea peptases, consist of the following components in percentage by weight: subtilin 0%-30%；Tyrothricin 10%-20%；Hydrolysising protease 8%-16%；Lipase 10%-20%；Glucokinase 2%-6%；α-amino acid injection-800 2%-8%；Quercitin 2%-8%；Remaining is carrier.By adopting the above-described technical solution, compared with prior art, the invention has the advantages that passing through the specific culture of isolated peptase of beneficial bacterium, inhibit bacterial virus proliferation, accelerate liver metabolism toxin, and repair wounded hepatocytes, achievees the purpose that the prevention birth comprehensive diarrhea of sucking pig.
Description
Technical field
The present invention relates to agriculture and animal husbandry technical fields.
Specifically, being to be related to a kind of novel prevention sucking pig diarrhea peptase and preparation method thereof.
Background technique
For sucking pig because not yet establishing stable microecosystem in enteron aisle, itself resistance is lower, sensitive to environmental stimuli, easily
Invasion and various stress factors by various pathogenic microorganisms are influenced, and sucking pig bacterium is given in especially sow vertical transmission, virus,
The pathogenic microorganisms such as toxin and toxin, easily cause 1-3 days watery diarrheas of nascent sucking pig, and the death rate reaches 90-100%.
Such as:
Transmissible gastroenteritis of swine is caused by transmissible gastro-enteritis virus, the pig at various ages can be infected, with 1-3 age in days with cream
Pig morbidity and mortality highest, the young age sucking pig death rate is up to 100%.
Sucking pig Huang dysentery is acute, the lethal infectious diseases of nascent sucking pig.Sucking pig in 1 week old is taken place mostly in, with 1-3 days
Age is most commonly seen, and disease incidence 90% and the death rate 50% are very high.
Sucking pig paratyphoid, is caused by salmonella infection.Mainly it is mainly in 1-2 monthly age sucking pig.
The red dysentery of sucking pig, was caused by the exotoxin of c-type clostridieum welchii, takes place mostly in the sucking pig within 1 week old, with 1-3 days
Age new life sucking pig is common, accidental to be born in 2-4 week old sucking pig below.
The prior art generallys use simple injection or oral antibiotic treatment, beneficial bacterium, the side such as sow antibody passive immunity
Method,
Single class antibiotic such as antibiotic trichomonas net, Enrofloxacin, gentamicin, streptomysin, Amoxicillin, sulfamido, terramycin
Class, it is only effective to a few virus or bacterium, and it is invalid to other viruses or bacteriums, overall efficiency is beneficial 10% or so
Bacterium therapy cannot be colonized rapidly in enteron aisle, and stable intestinal flora balance purpose is not achieved, and antibody passive immunity method belongs to special
Qualitative antibody is invalid to toxin and other viruses.
Existing technology solves Single-issue and side effect and is more toxic.
Summary of the invention
It is an object of the invention to overcome the shortcoming of above-mentioned traditional technology, a kind of novel prevention sucking pig abdomen is provided
Peptase and preparation method thereof is rushed down, the peptase that this technology is extracted using the fermentation of multiple beneficial bacterium prevents sucking pig by low dose oral
Diarrhea.
The purpose of the present invention is what is reached by following technical measures:
A kind of novel prevention sucking pig diarrhea peptase, consists of the following components in percentage by weight:
Subtilin 20%-30%；
Tyrothricin 10%-20%；
Hydrolysising protease 8%-16%；
Lipase 10%-20%；
Glucokinase 2%-6%；
α-amino acid injection-800 2%-8%；
Quercitin 2%-8%；
Remaining is carrier.
As an improvement: it consists of the following components in percentage by weight:
Subtilin 20%；
Tyrothricin 10%；
Hydrolysising protease 8%；
Lipase 20%；
Glucokinase 6%；
α-amino acid injection-800 8%；
Quercitin 8%；
Remaining is carrier.
As an improvement: it consists of the following components in percentage by weight:
Subtilin 30%；
Tyrothricin 20%；
Hydrolysising protease 16%；
Lipase 10%；
Glucokinase 2%；
α-amino acid injection-800 2%；
Quercitin 2%；
Remaining is carrier.
As an improvement: it consists of the following components in percentage by weight:
Subtilin 25%；
Tyrothricin 15%；
Hydrolysising protease 11%；
Lipase 15%；
Glucokinase 4%；
α-amino acid injection-800 5%；
Quercitin 5%；
Remaining is carrier.
As an improvement: the carrier is alumino-silicate.
As an improvement: the following steps are included:
S1, mixing weigh the component of each weight percent weight/power ratio as described in the appended claim 1, are uniformly mixed；
S2, storage.
As an improvement: in step sl, mixing temperature is less than 25 DEG C.
As an improvement: in step sl, antistatic mixing machine is used when mixing.
As an improvement: in step s 2, storage temperature is less than 15 DEG C.
As an improvement: in step s 2, when storage, avoids illumination and ultraviolet light from irradiating.
Action principle of the invention is proteolytic enzymes hydrolize albumen, plays important work to animal bacteria, virus infection
With promoting the phagocytosis opsonic action of mononuclear macrophage, neutralizing bacteriotoxin toxicity and combining with viral antigen makes viral mistake
Go infection host cell ability.
Protein hydrolysate can mediate conditioning phagocytosis, and body mucosal defense is mainly covered on the surface of intestines and mucous membrane of urinary bladder,
Inhibit microorganism to adhere in intestinal mucosa, slow down virus breeding, be important mucosal barrier, to certain viruses, bacteriums and general anti-
Original has antibody activity, prevents pathogen from invading body.So protein hydrolysate can have Efficient antibacterial, bacteriolyze, promote phagocytosis and coagulate
Collection effect, plays an important role in defence early stage body.
Lipase, lipase are present in the animal and plant and microorganism (such as mould, bacterium) tissue containing fat, rouge
Fat enzyme can destroy the cell membrane of bacterium, influence bacterial antigens, and bacterium is made to lose infection cell ability, due to breaking for cell membrane
Bad, antibacterial material is easier to enter inside bacterium, inhibits bacterial activity.
Subtilin, molecular formula C66H103N17O16S, off-white color or flaxen powder；It is odorless, bitter；Have draw it is wet
Property；It is easily oxidized agent destruction, it in the solution can be by various heavy precipitation of salts.This product is readily soluble in water, dissolves in ethanol,
It is insoluble in acetone, chloroform or ether.To gram-positive bacteria and negative cocci, Diplococcus pneumopniae, staphylococcus, gonococcus,
Diplococcus meningitidis and conveyor screw etc. have bactericidal effect.
Tyrothricin, molecular formula: C65H85N11O13 is the ring type polypeptide from bacillus brevis-antibiotic mixing
Object.It is to the effective topically effective antibiotic of gram-positive bacterium.It sometimes in conjunction with benzocainum 5mg with provide from
The alleviation of sore throat.In whole body intake, serious side effect can lead to, therefore, using being confined to local application.
Quercitin, quercitin are a kind of flavonoid monomer compounds being widely present in plant, are had anti-oxidant, anti-swollen
The multiple pharmacological effects such as tumor, hypoglycemic, reducing blood lipid.Quercitin has certain anti-inflammatory activity, is mainly shown as cause inflammatory factor
Inhibiting effect.
Gene repair damages various types of base and is identified by glucokinase, utilizes specific sequence
Column oligonucleotides looks for the sequence matched with it into DNA or RNA, and in connection, repairs damaged cell.
α-amino acid injection-800 can enhance glucose phosphate esterase active, promote phosphatide absorption and the synthesis of brain albumen, make tissue generation
The activity of thanking is vigorous, improves blood circulation, increases cerebral blood flow (CBF), enhances cell anti-anoxia ability, restores cell function.
In the present invention, proteolytic enzymes hydrolize albumen is defendd as the early stage of body；Lipase, lipase be present in containing
In the animal and plant and microorganism (such as mould, bacterium) tissue of fat, lipase can destroy the cell membrane of bacterium, facilitate withered
Lavendustin, tyrothricin and quercitin enter inside bacterium, inhibit bacterial activity or kill bacterium, the mid-term as anti-inflammatory disinfection
Means；Glucokinase and α-amino acid injection-800 repair damaged cell, restore cell function, and the end as body is restored.
Three phases synergistic effect, the comprehensive diarrhea of effectively preventing advantageously ensure that the health of sucking pig.
New technology extracts different components by fermentation, and every kind of composition is added by order magnitude range, full and uniform mixing, by big
Amount is experiments have shown that and the authentic and valid comprehensive diarrhea of solution.
By adopting the above-described technical solution, compared with prior art, the invention has the advantages that passing through the specific training of beneficial bacterium
Nutrient inhibits bacterial virus proliferation, accelerates liver metabolism toxin, and repair wounded hepatocytes, reach and prevent lactogenesis out from peptase
The purpose of the comprehensive diarrhea of pig.
Specific embodiment
Embodiment 1: a kind of novel prevention sucking pig diarrhea peptase consists of the following components in percentage by weight:
Subtilin 20%；
Tyrothricin 10%；
Hydrolysising protease 8%；
Lipase 20%；
Glucokinase 6%；
α-amino acid injection-800 8%；
Quercitin 8%；
Remaining is carrier.
The carrier is alumino-silicate.
The preparation method of novel prevention sucking pig diarrhea peptase described in embodiment 1, comprising the following steps:
S1, mixing weigh the component of each weight percent weight/power ratio as described in the appended claim 1, are uniformly mixed；
25 DEG C of mixing temperature；
Antistatic mixing machine is used when mixing.
S2, storage, avoid illumination and ultraviolet light from irradiating by 15 DEG C of storage temperature.
Embodiment 2: a kind of novel prevention sucking pig diarrhea peptase consists of the following components in percentage by weight:
Subtilin 30%；
Tyrothricin 20%；
Hydrolysising protease 16%；
Lipase 10%；
Glucokinase 2%；
α-amino acid injection-800 2%；
Quercitin 2%；
Remaining is carrier.
The carrier is alumino-silicate.
The preparation method of novel prevention sucking pig diarrhea peptase described in embodiment 2, comprising the following steps:
S1, mixing weigh the component of each weight percent weight/power ratio as described in the appended claim 1, are uniformly mixed；
15 DEG C of mixing temperature；
Antistatic mixing machine is used when mixing.
S2, storage, storage temperature avoid illumination and ultraviolet light from irradiating less than 10 DEG C.
Embodiment 3: a kind of novel prevention sucking pig diarrhea peptase consists of the following components in percentage by weight:
Subtilin 25%；
Tyrothricin 15%；
Hydrolysising protease 11%；
Lipase 15%；
Glucokinase 4%；
α-amino acid injection-800 5%；
Quercitin 5%；
Remaining is carrier.
The carrier is alumino-silicate.
The preparation method of novel prevention sucking pig diarrhea peptase described in embodiment 3, comprising the following steps:
S1, mixing weigh the component of each weight percent weight/power ratio as described in the appended claim 1, are uniformly mixed；
5 DEG C of mixing temperature；
Antistatic mixing machine is used when mixing.
S2, storage, storage temperature avoid illumination and ultraviolet light from irradiating less than 5 DEG C.
Experimental example:
Test site: Shandong Weifang.
Experimental animal: it is 3000 total to choose nascent sucking pig.It is divided into 3 groups, every group 1000.One group is set as normal control
Group, another group is set as administration control group, and one group is set as test group.
Wherein, novel 3.3 grams of prevention sucking pig diarrhea peptase as described in the present invention are gavaged in test group birth 3 hours, often
Its primary, 3 days course for the treatment of, serious person can early, evening respectively gavage it is primary.
In use, the novel prevention sucking pig diarrhea peptase as described in the present invention is diluted using 10% glucose solution
To 0.8g/ milliliters.
Wherein, Normal group is normally fed.
Wherein, test group gavages streptomysin, and the dosage of the streptomysin makes according to the different by specifications of streptomysin product
With 3 days courses for the treatment of.
As a result it is rolled over point:
Table 1 is test sucking pig diarrhea situation.
Wherein, efficient calculation method is (Normal group diarrhea pig's head number-test group diarrhea pig's head number)/normal right
According to a group diarrhea pig's head number.
Wherein, the calculation method of survival rate is (diarrhea pig's head number-death pig's head number)/diarrhea pig's head number.
Experimental result: the effective percentage of novel prevention sucking pig diarrhea peptase of the present invention is 94%-97.5%.
One embodiment of the present invention has been described in detail above, but the content is only preferable implementation of the invention
Example, should not be considered as limiting the scope of the invention.It is all according to all the changes and improvements made by the present patent application range
Deng should all fall within the scope of the patent of the present invention.
Claims (10)
1. a kind of novel prevention sucking pig diarrhea peptase, it is characterised in that: consist of the following components in percentage by weight:
Subtilin 20%-30%；
Tyrothricin 10%-20%；
Hydrolysising protease 8%-16%；
Lipase 10%-20%；
Glucokinase 2%-6%；
α-amino acid injection-800 2%-8%；
Quercitin 2%-8%；
Remaining is carrier.
2. novel prevention sucking pig diarrhea peptase according to claim 1, it is characterised in that: by the group of following weight percent
It is grouped as:
Subtilin 20%；
Tyrothricin 10%；
Hydrolysising protease 8%；
Lipase 20%；
Glucokinase 6%；
α-amino acid injection-800 8%；
Quercitin 8%；
Remaining is carrier.
3. novel prevention sucking pig diarrhea peptase according to claim 1, it is characterised in that: by the group of following weight percent
It is grouped as:
Subtilin 30%；
Tyrothricin 20%；
Hydrolysising protease 16%；
Lipase 10%；
Glucokinase 2%；
α-amino acid injection-800 2%；
Quercitin 2%；
Remaining is carrier.
4. novel prevention sucking pig diarrhea peptase according to claim 1, it is characterised in that: by the group of following weight percent
It is grouped as:
Subtilin 25%；
Tyrothricin 15%；
Hydrolysising protease 11%；
Lipase 15%；
Glucokinase 4%；
α-amino acid injection-800 5%；
Quercitin 5%；
Remaining is carrier.
5. novel prevention sucking pig diarrhea peptase according to claim 1, it is characterised in that: the carrier is alumino-silicate.
6. the preparation method of novel prevention sucking pig diarrhea peptase as described in claim 1, it is characterised in that: including following step
It is rapid:
S1, mixing weigh the component of each weight percent weight/power ratio as described in the appended claim 1, are uniformly mixed；
S2, storage.
7. the preparation method of novel prevention sucking pig diarrhea peptase as claimed in claim 6, it is characterised in that: in step sl,
Mixing temperature is less than 25 DEG C.
8. the preparation method of novel prevention sucking pig diarrhea peptase as claimed in claim 6, it is characterised in that: in step sl,
Antistatic mixing machine is used when mixing.
9. the preparation method of novel prevention sucking pig diarrhea peptase as claimed in claim 6, it is characterised in that: in step s 2,
Storage temperature is less than 15 DEG C.
10. the preparation method of novel prevention sucking pig diarrhea peptase as claimed in claim 6, it is characterised in that: in step s 2,
Illumination and ultraviolet light is avoided to irradiate when storage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811599053.4A CN109464653A (en) | 2018-12-26 | 2018-12-26 | A kind of novel prevention sucking pig diarrhea peptase and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811599053.4A CN109464653A (en) | 2018-12-26 | 2018-12-26 | A kind of novel prevention sucking pig diarrhea peptase and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109464653A true CN109464653A (en) | 2019-03-15 |
Family
ID=65676879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811599053.4A Pending CN109464653A (en) | 2018-12-26 | 2018-12-26 | A kind of novel prevention sucking pig diarrhea peptase and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109464653A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110141659A (en) * | 2019-06-10 | 2019-08-20 | 山东利邦牧业股份有限公司 | A kind of novel enhanced livestock and poultry Abwehrkraft des Koepers activity peptase and preparation method |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101053368A (en) * | 2007-04-25 | 2007-10-17 | 广州市维特福生物科技有限公司 | Feed additive |
| CN101978852A (en) * | 2010-09-06 | 2011-02-23 | 成都和谐生物科技有限公司 | Microbial feed additive for treating piglet yellow and white dysentery and preparation method thereof |
| CN104273342A (en) * | 2014-10-10 | 2015-01-14 | 广州华农大实验兽药有限公司 | Preparation method of composite feed additive containing lipase and lactic acid bacteria |
| CN104480047A (en) * | 2014-12-20 | 2015-04-01 | 湖北博大高科生物技术有限公司 | Bacillus subtilis HS11BD1 strain capable of producing subtilin in high yield and application thereof |
| CN104970224A (en) * | 2015-06-12 | 2015-10-14 | 青岛大信饲料有限公司 | Composition and mixed feed for preventing and treating porcine epizootic diarrhea |
| CN105255934A (en) * | 2015-11-23 | 2016-01-20 | 江南大学 | Strategy for efficiently coproducing alpha-aminobutyric acid and gluconic acid |
-
2018
- 2018-12-26 CN CN201811599053.4A patent/CN109464653A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101053368A (en) * | 2007-04-25 | 2007-10-17 | 广州市维特福生物科技有限公司 | Feed additive |
| CN101978852A (en) * | 2010-09-06 | 2011-02-23 | 成都和谐生物科技有限公司 | Microbial feed additive for treating piglet yellow and white dysentery and preparation method thereof |
| CN104273342A (en) * | 2014-10-10 | 2015-01-14 | 广州华农大实验兽药有限公司 | Preparation method of composite feed additive containing lipase and lactic acid bacteria |
| CN104480047A (en) * | 2014-12-20 | 2015-04-01 | 湖北博大高科生物技术有限公司 | Bacillus subtilis HS11BD1 strain capable of producing subtilin in high yield and application thereof |
| CN104970224A (en) * | 2015-06-12 | 2015-10-14 | 青岛大信饲料有限公司 | Composition and mixed feed for preventing and treating porcine epizootic diarrhea |
| CN105255934A (en) * | 2015-11-23 | 2016-01-20 | 江南大学 | Strategy for efficiently coproducing alpha-aminobutyric acid and gluconic acid |
Non-Patent Citations (6)
| Title |
|---|
| （日）中村良一: "《临床家畜内科治疗学》", 30 June 1987, 哈尔滨：黑龙江人民出版社 * |
| 刘建，等: "《兽药和饲料添加剂手册》", 31 August 2001, 上海：上海科学技术文献出版社 * |
| 吴木潮，等: "《胰岛β细胞 基础与临床》", 30 June 2017, 广州：广东科技出版社 * |
| 李强，等: "《新编常用中药有效成分手册》", 31 January 2007, 北京：中国协和医科大学出版社 * |
| 陈吉生: "《新编临床药物学》", 31 August 2013, 北京：中国中医药出版社 * |
| 陈斌: "《猪生产》", 31 August 2012, 郑州：河南科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110141659A (en) * | 2019-06-10 | 2019-08-20 | 山东利邦牧业股份有限公司 | A kind of novel enhanced livestock and poultry Abwehrkraft des Koepers activity peptase and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Effects of the antimicrobial peptide cecropin AD on performance and intestinal health in weaned piglets challenged with Escherichia coli | |
| CN103549222B (en) | Compound feed additive for preventing piglet diarrhea and preparation method thereof | |
| DK2224918T3 (en) | The use of EDTA and its salts for the prevention and treatment of bacterial intestinal diseases of pigs | |
| Hassan et al. | Innovative drugs, chemicals, and enzymes within the animal production chain | |
| CN102697784B (en) | Enrofloxacin injection for livestock and preparation method thereof | |
| CN110692863A (en) | Plant extract feed additive for improving liver and intestine protecting capability of tilapia | |
| Wu et al. | Effect of glutamine on the intestinal function and health of broilers challenged with Salmonella pullorum | |
| CN105125574A (en) | Formula and preparation process of polyhexamethylene guanidine drug powder for beasts and birds | |
| KR102382930B1 (en) | Anti-diarrhea formulation which avoids antimicrobial resistance | |
| KR950011733B1 (en) | Disease resistance ration and feed additive for cattles and swines | |
| CN109464653A (en) | A kind of novel prevention sucking pig diarrhea peptase and preparation method thereof | |
| CN105616485A (en) | Doxycycline hydrochloride and origanum oil composition | |
| CN115517367B (en) | Application of lactobacillus paracasei SMN-LBK in preparation of intestinal health promoting product | |
| CN102614294B (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| CN110464791A (en) | A kind of application of yucca spp in prevention chicken necrotizing enterocolitis | |
| CN103721240B (en) | Compound formulation for treating bacterial infection of digestive tract of livestock and poultry and preparation method of compound formulation | |
| CN108670951A (en) | A kind of compound sustained-released injection of gentamicin sulphate-Lincomycin Hydrochloride for animals and preparation method thereof | |
| CN109276602A (en) | Purposes of emblic and combinations thereof and composition purposes | |
| CN102698244B (en) | Drug composition used for preventing piglets from diarrhea and promoting piglets to grow | |
| CN113967243B (en) | Fermented traditional Chinese medicine preparation for preventing and treating diarrhea of poultry and preparation method thereof | |
| US20210128695A1 (en) | Ovotransferrin treatment for the reproductive tract | |
| CN104758347B (en) | Traditional Chinese medicine oral liquid for treating pullorum disease and preparation method thereof | |
| CN102847160B (en) | Compound quinolone injection for livestock, and preparation method thereof | |
| CN114041533A (en) | Antibiotic-free feed additive for preventing and controlling calf diarrhea and preparation method and using method thereof | |
| WO2017193509A1 (en) | Bionic gynecological lotion and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190315 |
|
| RJ01 | Rejection of invention patent application after publication |